Measurement of somatostatin receptor subtype 2 mRNA in breast cancer and corresponding normal tissue.

in Endocrine-Related Cancer
Authors:
C Orlando Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.

Search for other papers by C Orlando in
Current site
Google Scholar
PubMed Close
,
C Casini Raggi Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.

Search for other papers by C Casini Raggi in
Current site
Google Scholar
PubMed Close
,
S Bianchi Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.

Search for other papers by S Bianchi in
Current site
Google Scholar
PubMed Close
,
V Distante Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.

Search for other papers by V Distante in
Current site
Google Scholar
PubMed Close
,
L Simi Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.

Search for other papers by L Simi in
Current site
Google Scholar
PubMed Close
,
V Vezzosi Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.

Search for other papers by V Vezzosi in
Current site
Google Scholar
PubMed Close
,
S Gelmini Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.

Search for other papers by S Gelmini in
Current site
Google Scholar
PubMed Close
,
P Pinzani Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.

Search for other papers by P Pinzani in
Current site
Google Scholar
PubMed Close
,
M Cameron Smith Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.

Search for other papers by M Cameron Smith in
Current site
Google Scholar
PubMed Close
,
A Buonamano Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.

Search for other papers by A Buonamano in
Current site
Google Scholar
PubMed Close
,
E Lazzeri Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.

Search for other papers by E Lazzeri in
Current site
Google Scholar
PubMed Close
,
M Pazzagli Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.

Search for other papers by M Pazzagli in
Current site
Google Scholar
PubMed Close
,
L Cataliotti Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.

Search for other papers by L Cataliotti in
Current site
Google Scholar
PubMed Close
,
M Maggi Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.

Search for other papers by M Maggi in
Current site
Google Scholar
PubMed Close
, and
M Serio Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.

Search for other papers by M Serio in
Current site
Google Scholar
PubMed Close
DOI:
https://doi.org/10.1677/erc.0.0110323
Volume/Issue:
Volume 11: Issue 2
Article Type:
Abstract
Page Range:
323–332
Online Publication Date:
Jun 2004
Free access

Sign up for journal news

Somatostatin analogs are effective in inhibiting growth of human breast cancer cell lines. These antiproliferative effects are mediated by specific receptors located on cell membranes. The somatostatin receptor subtype 2 (sst2) is the principal mediator of somatostatin effects in normal and cancer cells, and its presence has already been demonstrated in breast cancer. The purpose of our study was to evaluate the clinical relevance of the expression of sst2 by quantifying its mRNA in a large group of infiltrating breast cancers and their corresponding normal tissues. The expression of sst2 mRNA was measured with quantitative real time RT-PCR in 169 breast cancers and in their corresponding unaffected tissues. We evaluated the association of sst2 expression with the commonest clinical-pathologic features of breast cancer. The correlation with a marker of cell proliferation (Ki-67) and with receptor concentration was also evaluated. In cancer tissues, we found that the absolute concentrations of sst2 mRNA were significantly higher in estrogen receptor (ER)-positive samples (P=0.002) as well as in lymph-node-negative cancers (P=0.04) (Student's t-test or one-way ANOVA). In addition, sst2 mRNA was significantly higher in breast cancers than in corresponding unaffected tissues (P=0.0002). However, when the clinical-pathologic parameters were considered, this gradient maintained its statistical significance only in tumors expressing positive prognostic markers, such as the presence of ER (P=0.0005) and progesterone receptors (PgR) (P=0005), and the lack of lymph-node involvement (P=0.0003). The same difference was also significant in postmenopausal women (P=0.001) and in T1 patients (P=0.001). In addition, sst2 mRNA expression was significantly higher (P=0.008) in low-proliferating breast cancers. Finally, we found that the quantitative expression of sst2 mRNA was directly related to the PgR concentration in breast cancer tissues (P<0.001). Our data seem to indicate that an upregulation of sst2 gene expression is a common feature of breast cancers which, on the basis of conventional predictive parameters, are expected to have a better prognosis. Featuring a possible role of somatostatin analogs in combined endocrine therapies for breast cancer, our results seem to confirm that the sst2 status of the tumor should be previously investigated.

Endocrine-Related Cancer is committed to supporting researchers in demonstrating the impact of their articles published in the journal.

The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.

More information is on the Reasons to publish page.

Sept 2018 onwards Past Year Past 30 Days
Full Text Views 951 789 108
PDF Downloads 139 78 9

 

  • Collapse
  • Expand
Print ISSN:
1351-0088
Online ISSN:
1479-6821
Page(s):
10
Print Publication Date:
01 Jan 2004
Online Publication Date:
Jun 2004